January 28, 2015 7:52 AM ET

Pharmaceuticals

Company Overview of Neuro3d S.A.

Company Overview

As of March 29, 2007, Neuro3d S.A. was acquired by Evotec AG. Neuro3d S.A., a biopharmaceutical company, engages in the discovery and development of treatment drugs for psychiatric disorders. Its drug portfolio includes ocaperidone for schizophrenia patients and ND1251 for the treatment of depression, as well as ND7001, a psychoactive drug with antidepressant-like and anxiolytic effects in animals. Neuro3d S.A. was founded in 2000 and is headquartered in Mulhouse, France.

130, rue de la Mer Rouge

Mulhouse,  68200

France

Founded in 2000

Phone:

33 3 89 36 91 70

Fax:

33 3 89 36 91 78

Key Executives for Neuro3d S.A.

Neuro3d S.A. does not have any Key Executives recorded.

Similar Private Companies By Industry

Company Name Region
Ventana Medical Systems SA Europe
Janssen-Cilag Europe
PPG-Sipsy SAS Europe
ANIMADERM Europe
United Pharmaceuticals SAS Europe

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Neuro3d S.A., please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.